Central Pacific Bank Trust Division Has $118,000 Holdings in Insulet Co. (NASDAQ:PODD)

Central Pacific Bank Trust Division raised its position in Insulet Co. (NASDAQ:PODD) by 23.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 505 shares of the medical instruments supplier’s stock after purchasing an additional 95 shares during the quarter. Central Pacific Bank Trust Division’s holdings in Insulet were worth $118,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Marshall Wace LLP acquired a new position in shares of Insulet during the 2nd quarter worth about $99,978,000. Baillie Gifford & Co. increased its position in shares of Insulet by 30.8% during the 2nd quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock worth $380,607,000 after purchasing an additional 443,783 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Insulet by 56.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 878,529 shares of the medical instruments supplier’s stock worth $190,623,000 after purchasing an additional 316,649 shares in the last quarter. Canada Pension Plan Investment Board boosted its holdings in shares of Insulet by 206.9% in the 1st quarter. Canada Pension Plan Investment Board now owns 429,591 shares of the medical instruments supplier’s stock valued at $73,632,000 after buying an additional 289,591 shares during the last quarter. Finally, Los Angeles Capital Management LLC grew its stake in shares of Insulet by 462.3% in the first quarter. Los Angeles Capital Management LLC now owns 299,654 shares of the medical instruments supplier’s stock valued at $51,361,000 after buying an additional 246,364 shares in the last quarter.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. BTIG Research cut their price target on shares of Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, August 9th. UBS Group boosted their price target on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. OTR Global reaffirmed a “mixed” rating on shares of Insulet in a research report on Monday, June 10th. Barclays boosted their target price on Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Finally, Canaccord Genuity Group raised their price target on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $234.60.

Insulet Stock Down 0.0 %

Shares of NASDAQ:PODD opened at $229.94 on Friday. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60. Insulet Co. has a 52-week low of $125.82 and a 52-week high of $243.98. The business’s 50 day simple moving average is $209.88 and its two-hundred day simple moving average is $192.02. The firm has a market cap of $16.10 billion, a P/E ratio of 69.68, a PEG ratio of 4.34 and a beta of 1.21.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.56 by ($0.01). The business had revenue of $488.50 million for the quarter, compared to analyst estimates of $488.00 million. Insulet had a return on equity of 30.73% and a net margin of 21.11%. The business’s quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.38 EPS. As a group, research analysts forecast that Insulet Co. will post 3.04 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.